The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European ...

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The ...

Competition in the ever-growing market for obesity treatments continues to mount, with positive early data for Hong Kong’s ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

Johnson & Johnson presented its financial results for the last quarter of 2024, the year as a whole, and its guidance for ...

Sino-American oncology company Shenzhen TargetRx has successfully completed its Series C financing, raising $50 million.

Chicago-based drug major AbbVie and privately-held San Diego firm Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets ...

Xilio Therapeutics reports mixed Phase II results for vilastobart with Tecentriq in colorectal cancer. While showing promise in some subsets with a 27% ORR, efficacy in patients with liver metastases ...

Sichuan Biokin Pharmaceutical and Shanghai Bao Pharmaceuticals are both ambitious about their ability to make an impact globally. Shanghai Bao uses its synthetic biology technology to develop and ...

And if you’re not thinking data first too - prioritizing your data quality - you risk falling behind your competition and missing out on valuable opportunities.

Patients For Affordable Drugs, Public Citizen, Social Security Works and other campaigners are to gather in Washington, DC next week with the aim of delivering a message to pharma.

Flagship Pioneering partners with CUHP and MTI to advance research, clinical translation, and talent development in the UK. The collaboration gives Flagship’s companies access to Cambridge’s resources ...